A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients with Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period

Trial Profile

A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients with Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Elobixibat (Primary)
  • Indications Constipation
  • Focus Registrational; Therapeutic Use
  • Acronyms Echo-2
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 28 Apr 2014 According to the ClinicalTrials.gov record, status changed from suspended to discontinued.
    • 29 Jan 2014 According to ClinicalTrials.gov record, status changed from recruiting to suspended.
    • 22 Jun 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2012-005588-28).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top